Join Richmond Pharmacology at this year s 10th Annual Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT), taking place on June 26-29 in Budapest, Hungary.The Congress will focus on key research and therapeutic areas, related challenges and latest achievements with the help of distinguished invited speakers, opinion leaders, experts and the upcoming future generation of clinical pharmacologists.We invite all attendees to join Richmond Pharmacology s Medical Director and Co-Founder Dr Ulrike Lorch at her presentation titled  frThe Use of Adaptive Study Design in Early Phase Clinical Research  scheduled for Day one, Session one at 10am.  For the full Scientific Programme of EACPT Congress please click here.In the last several years the interest in Adgaptive Study Design is evident from the growing amount of clinical research employing this model in the mid to later stages of medicines development.  Dr Lorch s presentation will describe where this design is of benefit to the conduct of First into Human and Early Phase Combination Studies and compare adaptive and conventional study design.  Little has been published on the practical application and merits of adaptive study design in Early Phase Clinical Research, so this presentation offers attendees a chance to learn more about the subject.If you would like to meet with Dr Ulrike Lorch, Richmond Pharmacology s CEO Dr Jorg Taubel.In the last several years the interest in Adaptive Study Design is evident from the growing amount of clinical research employing this model in the mid to later stages of medicines development.  Dr Lorchinfo@richmondpharmacology.com in advance to arrange a face-to-face meeting and discuss how Richmond Pharmacology can assist you with your current challenges.We hope to see you in Budapest to learn more about Richmond Pharmacology and enjoy one of Europe�s most lively cultural destinations.

Latest news

A first of a kind trial in the fight against malaria

June 12, 2024
Richmond successfully recruits and enrols adults of sub-Saharan ancestry who all complete a first of its kind trial in the treatment of malaria.
Read more

Patient with rare bleeding disorder becomes first to test new treatment

May 22, 2024
The thousands of patients who participate in Richmond’s trials are helping to advance medical science and save lives and, in the process, some make history. In a film released today, one trial participant tells her story.
Read more

Events

AHA Hypertension Scientific Sessions 2024

5 - 8 September 2024
Dr. Jörg Taubel, CEO of Richmond Pharmacology, will be attending the Hypertension 2024 Scientific Sessions
View event